Priorities for improvement in health in patients with rheumatoid arthritis (RA) who are starting disease-modifying antirheumatic drugs (DMARDs), including biological agents

被引：0
|
作者：
Heiberg, T
Vinders, M
Olsen, CL
Magnussen, AS
Enersen, TB
Fekete, S
Kvien, TK
机构：
[1] Ullevaal Univ Hosp, Dept Adm, Oslo, Norway
[2] Lillehammer Hosp Rheumat Dis, Dept Rheumatol, Lillehammer, Norway
[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[4] St Olav Hosp, Dept Rheumatol, Trondheim, Norway
[5] Buskerud Cent Hosp, Dept Rheumatol, Drammen, Norway
[6] Univ Hosp No Norway, Dept Rheumatol, Tromso, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [41] Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
    Nakamura, Jun
    Nagashima, Takao
    Nagatani, Katsuya
    Yoshio, Taku
    Iwamoto, Masahiro
    Minota, Seiji
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (05) : 470 - 475
  • [42] Corticosteroids and disease-modifying antirheumatic drugs for coronavirus disease 2019 in patients with rheumatoid arthritis
    Chen, Yu-Han
    Lee, Yuan-Ti
    Ma, Kevin Sheng-Kai
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (07) : 1391 - 1392
  • [43] DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
    Wang, Susan Siyu
    Lewis, Myles J.
    Pitzalis, Costantino
    BIOMEDICINES, 2023, 11 (07)
  • [44] Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
    Michael T. Nurmohamed
    Ben A. C. Dijkmans
    Drugs, 2005, 65 : 661 - 694
  • [45] Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis
    Nurmohamed, MT
    Dijkmans, BAC
    DRUGS, 2005, 65 (05) : 661 - 694
  • [46] Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs
    Sizova, Lyudmila
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (02) : 173 - 178
  • [47] THE EARLY USE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS
    MONGAN, ES
    ARTHRITIS AND RHEUMATISM, 1990, 33 (03): : 451 - 451
  • [48] EBM analysis: Classic DMARDs (disease-modifying antirheumatic drugs) and immunosuppressants in arthritis and uveitis
    Niehues, T.
    Winterhalter, S.
    Zierhut, M.
    Michels, H.
    Becker, M. D.
    Heiligenhaus, A.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2007, 224 (06) : 520 - 525
  • [49] THE USE OF COMBINATIONS OF DISEASE-MODIFYING ANTIRHEUMATIC AGENTS IN RHEUMATOID-ARTHRITIS
    PAULUS, HE
    ARTHRITIS AND RHEUMATISM, 1990, 33 (01): : 113 - 120
  • [50] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS - CURRENT CONCEPTS
    EMERY, P
    LUQMANI, R
    GORDON, C
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1994, 48 (02): : 82 - 86
12345